Aspire Biopharma amends 8-K to correct disclosure inaccuracies on preferred stock offering
PUBT · 4d ago
Share
Listen to the news
- Aspire Biopharma filed an amended Form 8-K to amend and restate an April 16, 2026 report to correct disclosure inaccuracies.
- Amendment updated disclosure on closing of second tranche of private placement of Series A Convertible Preferred Stock on April 15, 2026 for 12,500 shares with gross proceeds of about USD 10 million.
- Filing also clarified Series A Convertible Preferred Stock authorization to 30,000 shares with stated value of USD 1,000 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-017145), on April 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved